Entrada Therapeutics (TRDA) Net Cash Flow (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Net Cash Flow of -$14.6 million for Q1 2026, up 56.23% year-over-year from -$9.4 million in Q1 2025, and down 405.12% quarter-over-quarter from -$2.9 million in Q4 2025.
Entrada Therapeutics (TRDA) Net Cash Flow (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$14.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 56.23% year-over-year to -$14.6 million; the TTM figure through Mar 2026 stood at $7.9 million (up 1427.05% YoY), while the FY2025 annual figure was -$10.8 million, down 132.18% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$14.6 million, down from -$2.9 million in the prior quarter.
- The five-year high for Net Cash Flow was $182.5 million in Q1 2023, with the low at -$202.5 million in Q1 2022.
- The 5-year median for Net Cash Flow is -$2.9 million (2025), against an average of -$12.4 million.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow surged 292.79% in 2023, then sank 4101.68% in 2025.
- Entrada Therapeutics' Net Cash Flow stood at -$8.2 million in 2022, then soared by 292.79% to $15.7 million in 2023, then surged by 47.34% to $23.2 million in 2024, then slumped by 112.49% to -$2.9 million in 2025, then slumped by 405.12% to -$14.6 million in 2026.
- Business Quant data shows TRDA's Net Cash Flow at -$14.6 million in Q1 2026, -$2.9 million in Q4 2025, and $20.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 22.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.84 Mn |
| Jun 30, 2026 | 22.84 Mn |
| Mar 31, 2026 | -14.61 Mn |
| Mar 31, 2026 | -14.61 Mn |
| Dec 31, 2025 | -2.89 Mn |
| Dec 31, 2025 | -2.89 Mn |
| Sep 30, 2025 | 20.80 Mn |
| Sep 30, 2025 | 20.80 Mn |
| Jun 30, 2025 | 4.65 Mn |
| Jun 30, 2025 | 4.65 Mn |
| Mar 31, 2025 | -33.37 Mn |
| Mar 31, 2025 | -33.37 Mn |
| Dec 31, 2024 | 23.16 Mn |
| Dec 31, 2024 | 23.16 Mn |
| Sep 30, 2024 | -107.20 Mn |
| Sep 30, 2024 | -107.20 Mn |
| Jun 30, 2024 | 116.82 Mn |
| Jun 30, 2024 | 116.82 Mn |
| Mar 31, 2024 | 834,000.00 |
| Mar 31, 2024 | 834,000.00 |